Free Trial

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

+0.10 (+0.78%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
63,666 shs
Average Volume
156,914 shs
Market Capitalization
$640.98 million
P/E Ratio
Dividend Yield
Price Target

Mineralys Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
159.5% Upside
$33.50 Price Target
Short Interest
4.46% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$1,500 Sold Last Quarter
Proj. Earnings Growth
From ($2.94) to ($3.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

679th out of 920 stocks

Pharmaceutical Preparations Industry

306th out of 413 stocks

MLYS stock logo

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

MLYS Stock Price History

MLYS Stock News Headlines

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.6%
MLYS Jun 2024 12.500 call
MLYS Sep 2024 30.000 call
Mineralys Therapeutics Earnings Preview
Mineralys Therapeutics: A Story To Keep An Eye On
MLYS Apr 2024 15.000 call
MLYS Mar 2024 20.000 call
See More Headlines
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.87 per share


Free Float
Market Cap
$638.00 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Brian Taylor Slingsby M.D. (Age 47)
    M.P.H., Ph.D., Founder & Executive Chairman
    Comp: $69.33k
  • Mr. Jon Congleton (Age 61)
    CEO & Director
    Comp: $775.77k
  • Mr. Adam Scott Levy (Age 46)
    CFO & Secretary
    Comp: $655.58k
  • Dr. David M. Rodman M.D. (Age 69)
    Chief Medical Officer
    Comp: $726.95k
  • Ms. Cindy Berejikian
    Executive Vice President of Operations
  • Ms. Sarah Foster
    Vice President of Human Resources
  • Dr. Robert McKean Ph.D.
    Senior Vice President of CMC
  • Ms. Danielle Bradbury
    Senior Vice President of Quality Assurance
  • Mr. Jeffrey N. Fellows
    Senior Vice President of Regulatory Affairs
  • Ms. Jessica Ibbitson
    Senior Vice President of Clinical Operations

MLYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Mineralys Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLYS shares.
View MLYS analyst ratings
or view top-rated stocks.

What is Mineralys Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 1 year price objectives for Mineralys Therapeutics' stock. Their MLYS share price targets range from $30.00 to $37.00. On average, they expect the company's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 159.5% from the stock's current price.
View analysts price targets for MLYS
or view top-rated stocks among Wall Street analysts.

How have MLYS shares performed in 2024?

Mineralys Therapeutics' stock was trading at $8.60 at the beginning of 2024. Since then, MLYS shares have increased by 50.1% and is now trading at $12.91.
View the best growth stocks for 2024 here

When is Mineralys Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our MLYS earnings forecast

How were Mineralys Therapeutics' earnings last quarter?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) announced its earnings results on Thursday, March, 21st. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.24.

What ETFs hold Mineralys Therapeutics' stock?

ETFs with the largest weight of Mineralys Therapeutics (NASDAQ:MLYS) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) and

When did Mineralys Therapeutics IPO?

Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

Who are Mineralys Therapeutics' major shareholders?

Mineralys Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.77%), SR One Capital Management LP (4.06%), Vanguard Group Inc. (1.98%), Affinity Asset Advisors LLC (0.66%), Bellevue Group AG (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, LP and Samsara Biocapital Gp, Llc.
View institutional ownership trends

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLYS) was last updated on 5/21/2024 by Staff

From Our Partners